非小细胞肺癌脑转移治疗进展

Progress in the treatment of brain metastases from non-small cell lung cancer

脑部转移是非小细胞肺癌(non-small cell lung cancer,NSCLC)患者最常见的远处转移部位之一.NSCLC患者一旦出现脑部转移,治疗疗效不佳,预后极差.一直以来,脑部的放疗都是其标准治疗方式,但治疗效果欠佳.近年由于靶向药物的出现,驱动基因阳性NSCLC脑转移患者的生存期延长,因此靶向治疗药物的选择成为人们研究的热点.免疫治疗的出现使得NSCLC患者能从中获益,但免疫治疗在NSCLC脑转移患者的治疗中发挥怎样的作用,也成为许多学者关注的焦点.肺癌脑转移治疗仍有许多问题亟待解决,本文将对NSCLC脑转移治疗的研究进展进行综述,指导临床实践中治疗方案的抉择.

Brain metastasis is one of the most common distant metastasis sites in patients with non-small cell lung cancer(NSCLC).Once brain metastasis occurs in NSCLC patients,the therapeutic effect will be weak and the prognosis will be extremely poor.For a long time,radiotherapy for brain has been the standard treatment method,but the treatment effect is not satisfying.In recent years,due to the emergence of targeted drugs,the survival time of NSCLC patients with brain metastasis and positive driver gene is prolonged,so the selection of targeted therapeutic drugs has become a popular research topic.The emergence of immunotherapy enables NSCLC patients to benefit from it,but the role of immunotherapy in the treatment of NSCLC patients with brain metastases has also become the focus of many scholars'attention.There are still many problems to be solved in the treatment of brain metastases from lung cancer.This paper will review the research progress in the treatment of brain metastases from NSCLC to guide the choice of treatment scheme in clinical practice.